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Abstract  
Background 
Microvascular angina is caused by cardiac small vessel disease and dysregulation of 
the endothelin system is implicated. The minor G allele of the non-coding single 
nucleotide polymorphism (SNP) rs9349379 enhances expression of the endothelin 1 
gene in human vascular cells, increasing circulating concentrations of ET-1. The 
prevalence of this allele is higher in patients with ischemic heart disease.  Zibotentan 
is a potent, selective inhibitor of the ETA receptor. We have identified zibotentan as a 
potential disease-modifying therapy for patients with microvascular angina.  
Methods  
We will assess the efficacy and safety of adjunctive treatment with oral zibotentan (10 
mg daily) in patients with microvascular angina and assess whether rs9349379 
(minor G allele; population prevalence ~36%) acts as a theragnostic biomarker of the 
response to treatment with zibotentan.  
The Precision medicine with Zibotentan in microvascular angina (PRIZE) trial is a 
prospective, randomized, double-blind, placebo-controlled, sequential cross-over 
trial. The study population will be enriched to ensure a G-allele frequency of 50% for 
the rs9349379 SNP. The participants will receive a single-blind placebo run-in 
followed by treatment with either 10 mg of zibotentan daily for 12 weeks then 
placebo for 12 weeks, or vice versa, in random order.  The primary outcome is 
treadmill exercise duration using the Bruce protocol. The primary analysis will assess 
the within-subject difference in exercise duration following treatment with 
zibotentan versus placebo. 
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Conclusion 
PRIZE invokes precision medicine in microvascular angina. Should our hypotheses 
be confirmed, this developmental trial will inform the rationale and design for 
undertaking a larger multicenter trial. 
Clinical trial registration 
ClinicalTrials.gov registration: NCT04097314. 
Keywords 
Angina, ischemic heart disease, endothelin-1, randomized control trial, 
microvascular disease, exercise testing, precision medicine  
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Background 
Microvascular angina 
The term angina pectoris is derived from Latin, meaning “strangling of the chest”. (1) 
Angina is a consequence of myocardial ischemia caused by an imbalance between 
myocardial blood supply and oxygen demand. (2) Classically the management of 
patients with angina pectoris focuses on detection and treatment of flow-limiting 
epicardial coronary artery disease (CAD). (3) However, fewer than half of patients 
with suspected angina have evidence of obstructive CAD on coronary angiography. 
(4,5) Many patients with “normal” coronary angiography have signs, symptoms and 
investigations in-keeping with myocardial ischemia –this is  termed ischemia with 
non-obstructive coronary artery disease (INOCA).(6)  
INOCA is a heterogeneous group of conditions, including disorders of coronary 
anatomy, endothelial function and vasoreactivity.(7) A growing body of evidence 
supports the differentiation of this group into distinct disease endotypes – the most 
common being microvascular angina and epicardial coronary vasospasm – that are 
amenable to stratified medicine. (3,8) 
Microvascular angina is caused by coronary microvascular dysfunction. The 
Coronary Vasomotion Disorders International Study (COVADIS) Group define 
microvascular angina as symptoms of myocardial ischemia with proven coronary 
microvascular dysfunction (e.g. index of microcirculatory resistance (IMR) ≥25, 
coronary flow reserve (CFR) <2.0 or abnormal microvascular constriction during 
acetylcholine infusion), with unobstructed epicardial coronary arteries. (Table I) (9). 
The pathogenesis of microvascular angina is multi-factorial and incompletely 
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understood.  It may involve structural and/or functional abnormalities of the 
microvasculature. Standard invasive coronary angiography lacks the spatial 
resolution to image the microcirculation directly.(10) However, microvascular 
remodeling, with decreased luminal size and rarefaction (loss of capillaries) is 
implicated. (11) Functional microvascular angina involves enhanced vasoconstriction 
and/or impaired coronary vasodilatation in response to physiological (e.g. exercise) 
or pharmacological e.g. acetylcholine, adenosine, stimuli of the coronary 
microvasculature, with endothelium-dependent and independent mechanisms being 
demonstrated. (12)  
Zibotentan 
Endothelin-1 (ET-1) is a small peptide, produced primarily in the endothelium that is 
a potent constrictor of human blood vessels, and importantly is the most potent 
vasocontrict0r of the coronary arteries. (13–16)  ET-1 is mediated by two receptors: 
ETA and ETB. ETA activation by ET-1  mediates coronary vasoconstriction. (17–19) 
Microvascular angina is associated with elevated circulating concentrations of ET-1 
and prolonged exposure to ‘excess’ endothelin has harmful effects on small vessel 
function. (20,21) Additionally, ET-1 mediates enhanced vasoconstriction in the 
peripheral arterioles of patients with microvascular angina compared to control 
subjects. (22)  
Two trials of ET-1 receptor antagonists in patients with microvascular angina 
reported favorable, preliminary results (Reriani NCT00271492; Johnson 
NCT00738049). However, these trials were limited in size and unfortunately both 
atrasentan (hormone-refractory prostate cancer) and darusentan (resistant 
hypertension) were subsequently discontinued following neutral results from phase 
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III trials relating to their primary indications, thus stopping any further investigation 
of their potential application in microvascular angina. (23,24)   
There are theoretical benefits to selective ETA receptor antagonism in cardiovascular 
disease, given that non-selective ETA and ETB receptor antagonists in heart failure 
cause deleterious fluid retention and adverse outcomes. Supportive evidence of ETA 
selective antagonism can be drawn from studies in the population with heart failure 
and preserved ejection fraction (HFpEF). The natural history of these conditions is 
linked with microvascular angina reflecting chronic myocardial ischemia that may 
lead to HFpEF in the longer term (25). A double-blind, placebo-controlled, 
randomized controlled trial of sitaxentan in patients with HFpEF disclosed 
improvements in exercise tolerance conferred by this ETA receptor antagonist. (26) 
Zibotentan is a potent inhibitor of the ETA eceptor with no “off-target” binding to  
the ETB receptor.(27)  We have identified zibotentan as a potential disease-modifying 
therapy for patients suffering from microvascular angina; however, it has not been 
used before in this patient group and is currently unlicensed. Zibotentan was initially 
developed as a possible treatment for cancer, but it did not improve survival in this 
group of patients.(28) With the support of the AstraZeneca Open Innovation 
programme, we have developed a clinical pathway for repurposing zibotentan as a 
novel treatment for patients with microvascular angina. The safety, 
pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of orally administered 
zibotentan have been examined in 20 Phase I studies, 4 Phase II studies and 3 Phase 
III studies. (29)  
The dose being used in this study is 10 mg once daily (having been previously studied 
at doses up to 240mg in oncology studies) to achieve adequate target coverage over a 
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24-hour period, whilst minimizing side effects relating to ‘target engagement’ which 
include headache, nasal congestion/rhinitis, nausea and/or vomiting, and peripheral 
edema. (27,30) Importantly, zibotentan has been tested ex vivo at these 
concentrations and has been shown to fully reverse an established ET-1 
vasoconstriction, indicative of efficacy in conditions associated with vasospasm. (31) 
Clearance of zibotentan is reduced in patients with hepatic or renal impairment. (30)  
Zibotentan carries a risk of fetal toxicity and a theoretical risk of transfer via semen 
or breast milk.(29) Clinical risk in PRIZE will be mitigated by the exclusion of 
patients with a medical diagnosis that is associated with toxicity and specific 
guidance regarding women of child-bearing potential (WoCBP) and their partners. 
(Table II). 
Precision medicine in microvascular angina 
The chronic elevation of circulating ET-1 in microvascular angina may be influenced 
by genetic factors.  A gene variant of interest is rs9349379 – this is a common non-
coding single nucleotide polymorphism (SNP) in the third intron of the protein-
coding PHACTR1 gene on chromosome 6.(32) This SNP regulates expression of the 
Endothelin 1 (EDN1) gene in human vascular cells which encodes the ET-1 protein. 
The minor G allele of this SNP (population prevalence ~36%) is associated with 
significantly increased circulating concentrations of ET-1.(33)  
Emerging evidence from our laboratory (BHF CorMicA ClinicalTrials.gov: 
NCT03193294) indicates the prevalence of this SNP may be more common in 
patients with microvascular angina than is observed in age- and sex-matched 
controls.  Patients with the rs9349379 G allele had higher serum ET-1 and over 
double the odds of coronary microvascular dysfunction. Additionally, subjects were 
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more likely to have impaired myocardial perfusion and reduced exercise tolerance. 
(31)  
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Hypothesis 
Our hypothesis is that the ETA antagonist, zibotentan, will be an effective treatment 
for patients with microvascular angina.  We further hypothesize that the SNP 
regulator of EDN1 gene expression, rs9349379 (minor G allele), will act as a novel 
genomic theragnostic biomarker that associates with treatment response in this 
patient group. (Figure I) 
Aims 
1. To assess the efficacy of adjunctive treatment with zibotentan in patients with 
microvascular angina.  
2. To explore the mechanisms of any beneficial effects of zibotentan in 
microvascular angina. 
3. To assess genetic and clinical biomarkers for baseline patient characteristics 
and treatment response. 
4. To determine rates and severity of adverse events associated with zibotentan 
and evaluate its safety in a non-oncology population 
5. To explore the feasibility of the personalized medicine strategy in an ischemic 
heart disease population. 
Study Design 
The PRIZE trial has a prospective, randomized, double-blind, placebo-controlled, 
sequential cross-over design. The study population will be enriched to ensure the G-
allele frequency of the rs9349379 SNP is at least 50%. Participants will receive a 
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single-blind run-in with placebo followed by double-blind treatment with either 10 
mg of zibotentan daily for 12 weeks then placebo for 12 weeks, or vice versa, in 
random order. The trial is designed to assess the superiority of the addition of oral 
zibotentan to guideline-indicated therapy as compared with placebo and guideline-
indicated treatment for patients with microvascular angina. (Figure II)  
Setting 
The trial will involve multiple centers in the UK (Queen Elizabeth University 
Hospital (Glasgow), Royal Free Hospital (London), Blackpool Teaching Hospitals, 
Royal Papworth Hospital (Cambridge), Department of Cardiology in the Oxford 
University Hospitals NHS Foundation Trust and Division of Cardiovascular Medicine 
at the University of Oxford, John Radcliffe Hospital (Oxford), Guy’s & St. Thomas’ 
Hospital (London), University Hospitals of Leicester, Liverpool University Hospitals 
Foundation NHS Trust, (Liverpool) and the Leeds Teaching Hospitals NHS Trust. 
Additional sites may be included in order to ensure recruitment milestones are 
achieved. 
Patient identification 
Patients will be identified from clinical databases, clinics and clinical procedure lists. 
The clinical pathways include but are not limited to: (1) out-patient clinics including 
patients with a diagnosis of microvascular angina; (2) diagnostic stress tests, e.g. 
stress perfusion magnetic resonance imaging (MRI), stress echocardiography, stress 
nuclear imaging with PET or SPECT or an exercise ECG leading to a diagnosis of 
microvascular angina; (3) invasive or CT coronary angiography. 
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Eligibility criteria 
The inclusion criteria are: (1) age >18 years old; (2) microvascular angina; (3) able to 
comply with study procedures; (4) able to provide written informed consent.   
In PRIZE, we define microvascular angina as per the COVADIS guideline (Table I).  
The criteria are: 
1. Symptoms of myocardial ischemia 
2. Absence of obstructive CAD (>50% diameter reduction or FFR <0.80) by either CT 
or invasive coronary angiography. 
3. Objective evidence of myocardial ischemia 
4. Evidence of impaired coronary microvascular function 
In order to participate in this trial, the patient should have a diagnosis of 
microvascular angina (probable or definite). Probable microvascular angina is 
defined as having 3 of the 4 COVADIS criteria.  Definite microvascular angina 
requires all 4 COVADIS criteria. Participants in this trial should also fulfil criteria 1 & 
2. This diagnostic classification is endorsed by the European Society of Cardiology 
practice guidelines (August 2019). (3) 
The exclusion criteria are listed in Table II.  
Recruitment  
Three hundred and fifty-six patients will be enrolled following written informed 
consent. Those eligible on clinical grounds will undergo genotype blood testing. All 
those with the GG genotype will continue to the run-in phase, whereas only a 
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proportion of those with the AA and AG genotypes will proceed. This will boost the 
relative frequency of the G genotypes in the study population, with the objective of 
achieving 50% G allele frequency.  If a consented patient is found to be ineligible for 
the run-in/treatment phase of the randomized trial, they will remain included in the 
study population, including consent for long term follow up using linkage of 
electronic government and patient records (EPR). 
Following genotyping and enrichment of the study population with the minor G 
allele for the rs9349379 SNP we anticipate enrolling at least 144 patients into the 
run-in phase of the study. Allowing for up to 30% drop-out during run-in, at least 
100 participants will proceed to randomization. 
Genotyping 
Genomic DNA will be extracted from a peripheral blood sample (EDTA containing 
tube taken during Visit 1).  A Sanger sequencing approach, using the forward primer 
“F_GTGCAATTCTCCAAGGCTCC” and the reverse primer 
“R_TTTAAAACTCAGCTCGTGGAAAA”, will be used to sequence part of intron 3 of 
the PHACTR1 gene to determine the genotype of the rs9349379 SNP.  
Medical optimization 
Since microvascular angina is a chronic condition, most patients will already be 
established on maintenance drug therapy. In some cases, cardiovascular risk factors, 
including blood pressure and lipids, may not be optimally managed. To accurately 
assess the efficacy of zibotentan, we will first ensure that patients recruited to the 
study are being managed with guideline-directed medical therapy as per 
contemporary practice guidelines and local standards of care.  This process includes 
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informed consent (Visit 1) through to treatment run-in (Visit 2). The medical 
optimization period is intended to identify patients with unstable symptoms or 
uncontrolled cardiovascular risk factors. In affected cases, optimization of 
pharmacological and non-pharmacological treatments and will be carried out by 
clinical staff including clinical research nurses, study physicians and pharmacists, as 
clinically appropriate. 
The clinical review and optimization process will follow a standard operating 
procedure (SOP), in line with contemporary clinical practice guidelines, notably 
those issued by the European Society of Cardiology.(3) For logistical reasons, this 
optimization phase is limited to 6 weeks. If angina drug therapy is changed, then a 
period of 4 weeks will follow before proceeding into the treatment run-in phase.  
Following optimization, angina therapy will remain the same from entry into the 
treatment run-in period (Visit 2) and thereafter. 
Outcomes 
Primary outcome 
The primary outcome for our study is the treadmill exercise time (seconds) using the 
full Bruce exercise tolerance test protocol.(34) Exercise testing using the Bruce 
protocol is a standard of care in clinical cardiology and evidence-based for assessing 
functional capacity, susceptibility to effort-related anginal symptoms and ischemia in 
patients with stable angina.(35) Treadmill exercise time (s) is a reproducible 
outcome measure (35–42) with an approximately 10% test-retest variability. (36,42) 
In a study of repeated exercise testing in older women the intra-class correlation 
coefficient of exercise duration was 0.88.(38) In a clinical trial involving 33 patients 
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with microvascular angina, there was 100% compliance with serial exercise tests 
(n=4 per subject). Patient and Public Involvement (PPI) in the design of this study 
provided encouraging feedback to the effect that exercise tests are generally well 
tolerated. Treadmill exercise testing is also accepted by regulators, such as the 
Federal Drug Administration, for assessing the efficacy of angina medications.  
Secondary outcomes: 
The pre-specified secondary outcomes are described in Table III.  
The primary and secondary outcomes, and the MRI sub-study, are intended to 
provide surrogate outcome information that is mechanistically linked to the 
pathogenesis of microvascular angina. Accordingly, the results of our precision 
medicine trial should be informative about the potential role for zibotentan as a 
disease-modifying therapy for microvascular angina.  
Questionnaires 
The Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire 
that quantifies limitations caused by angina, the frequency of angina, treatment 
satisfaction, and subjective perception of quality of life. (43) Each component score is 
converted and collated to give a total score out of 100, where a higher score indicates 
better function. SAQ scores are independently associated with mortality, 
hospitalization, and resource use.(44–46) The SAQ is a sensitive instrument in 
patients with microvascular angina.(8) 
Self-reported health status will be assessed using the generic EuroQOL EQ-5D-5L 
questionnaire and the Brief Illness Perception Questionnaire (Brief-IPQ).(47,48)  
The Treatment Satisfaction Questionnaire (TSQM-9) will provide information 
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regarding medication  side effects, effectiveness, convenience and overall 
satisfaction.(49)We will  also utilize the PHQ–4 questionnaire that is a validated tool 
for detecting both anxiety and depressive disorders.(50) Participants will be invited 
to complete these questionnaires at each visit. 
Pharmacokinetics 
Blood samples will be obtained during Visits 3, 4 and 5 (Fig. II) to measure steady-
state plasma concentrations of zibotentan reflecting chronic treatment with the last 
dose being the preceding day. 
Adherence with trial medication will be assessed by participant-reported adherence 
with therapy (number of days with a missed dose during the preceding phase; 
duration of the phase (days); number of days with a missed dose in the past 7 days), 
and time of the last dose prior to the visit). 
Pharmacodynamics 
In order to research the mechanisms of any potential benefit of oral zibotentan on 
the described endpoints, we will compare the within-subject differences in the 
circulating concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), 
high sensitivity (hs) interleukin-6 (hsIL-6), ET-1, hs-troponin I, NT-proBNP, cystatin 
C, lipid profile, glucose, HbA1c, and hsCRP.  
The associations between the within-subject differences in circulating concentrations 
of these mechanistic biomarkers and the primary and secondary outcomes for 
efficacy and safety will be assessed.  
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Cardiovascular magnetic resonance imaging (MRI) sub-study 
Myocardial perfusion is generally impaired in patients with microvascular angina. 
The rational for undertaking the MRI sub-study is to determine whether, compared 
with placebo, treatment with zibotentan improves myocardial blood flow. Adenosine 
stress perfusion MRI is scheduled for 3 occasions in 60 participants. A detailed 
description of the sub-study is beyond the scope of this article and will be described 
separately in a future article. 
Angina diary 
The diagnostic performance of a custom-developed questionnaire for symptoms, 
quality of life and response to treatment will be assessed as an exploratory outcome. 
Participants will be invited to complete this diary each time symptoms occur during 
the trial.  
Feasibility 
This study has been peer reviewed by panel members of the Medical Research 
Council (MRC) Biomedical Catalyst Developmental Pathways Scheme and the MRC 
Stratified Medicine Board. Feedback has also been provided by the British Society of 
Cardiovascular Magnetic Resonance Research Group, the British Cardiovascular 
Society and the Cardiovascular Care Partnership (UK).  
Statistical considerations 
Sample size calculation 
The primary outcome is the treadmill exercise time (seconds). A 30-second 
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difference in exercise duration is considered clinically significant. (51–53) The 
standard deviation of the difference between two exercise test measurements is 
assumed to be 85 seconds. (51) To achieve 80% power to detect a mean difference of 
30s between treatments in a 2×2 crossover design and a level of significance of 0.05 
(alpha error) requires complete data in 65 subjects. At least 100 subjects will be 
randomized to allow for data quality issues and loss to follow-up. Considering the 
clinical optimization (visit 1-2) and single-blind placebo run-in (visit 2 to 3), we 
anticipate a drop-out of up to 30% may occur (n=42), meaning we will aim to have 
144 begin the run-in phase of the trial to randomize 100.  
Pre-specified subgroup analyses are intended for sex, a history of vasospastic angina 
and the duration of symptoms. 
rs9349379 SNP G-allele enrichment 
The study population will be enriched to achieve approximately 50% prevalence of 
the G allele of the rs9349379 SNP, by selectively including patients with the AA and 
AG genotypes.  
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The sampling rates of AA and AG patients will be set at the start of the trial, based on 
expected allele frequencies, but will be monitored during the trial, and may be 
modified, based on the genotype distribution achieved. This process will be 
monitored by the Trial Steering Committee. The enrichment process will be balanced 
against the rate of recruitment into the study, and if recruitment falls behind 
timelines, the sampling rates may be modified to increase the numbers randomized, 
at the expense of having a lower than 50% G allele frequency.  
Run-in phase 
Participants will enter a three-week run-in phase from Visit 2 to Visit 3. Participants 
will receive a once daily single blind placebo medication. The purpose of this run-in 
period is to give the participants experience of taking a study medication. Since 
assessments of adherence with study therapy and safety are objectives of the trial, we 
purposefully decided against a run-in phase with zibotentan, since participants who 
might be intolerant of the active treatment would then not be included in the trial.  
Randomization 
Randomization will occur during Visit 3, following successful completion of a single-
blind placebo run-in.  Eligible and consenting patients will be randomized with equal 
probability to the two groups reflecting the sequential order of zibotentan or placebo 
in Phase 1 and Phase 2, respectively: Group 1 = zibotentan in Phase 1 then placebo in 
Phase 2; Group 2 = placebo in Phase 1 then zibotentan in Phase 2. The 
randomization will be minimized with respect to a concomitant history of vasospastic 
angina, study site, genotype, and sex. 
Blinding 
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The study is double-blind. Specifically, the trial participants, carers, clinical staff, and 
researchers will be blinded to the intervention. Outcome assessments (endpoint 
adjudication) will be undertaken in blinded fashion.  
Breaking of the study blinding in an emergency will only be performed where 
knowledge of the treatment is absolutely necessary for further medical management 
of the patient. Any emergency unblinding will occur via a telephone Interactive Voice 
Response System (IVRS). Unblinding the treatment allocation may be required when 
reporting suspected unexpected serious adverse reactions (SUSARs) to the 
regulatory authorities. This will be performed by the sponsor pharmacovigilance 
office. 
Trial management and governance 
Trial management  
The trial will be conducted in line with the current Guidelines for Good Clinical 
Practice in Clinical Trials and CONSORT guidelines.(54,55) 
The Trial Management Group (TMG) includes those individuals responsible for the 
day-to-day management of the study including the chief investigator, project 
manager and representatives from the co-sponsors. The role of this group will be to 
facilitate the progress of the study, ensure that the protocol is adhered to and take 
appropriate action to safeguard participants and the quality of the study itself.  
A Trial Steering Committee (TSC) compromising of an independent chairperson, two 
independent cardiologists, a representative from the MRC and a patient 
representative has been formed to provide overall supervision of the trial and ensure 
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that it is being conducted in accordance with the principles of GCP and the relevant 
regulations. Decisions about continuation or termination of the trial or substantial 
amendments to the protocol will be the responsibility of the TSC who will advise the 
co-sponsors. 
An Independent Data Monitoring Committee (IDMC) including two independent 
medical experts and an independent biostatistician will receive unblinded reports on 
study safety data and on study progress/outcomes. The IDMC may recommend to 
the TSC and co-sponsors that the study should stop prematurely because of concerns 
about patient safety. 
Since the trial is a crossover trial, and not designed to assess between-group 
differences in clinical endpoints, a Clinical Event Committee is not required. The 
authors are solely responsible for the design and conduct of this study, all study 
analyses, the drafting and editing of the paper and its final contents. 
Ethics 
The PRIZE trial is approved by the UK National Research Ethics Service (Reference 
19/NE/0110). 
Sources of Funding 
PRIZE is an investigator-initiated clinical trial that is funded by the Medical 
Research Council (MR/S018905/1). The funder is represented on the TSC, but the 
representative has no role in the trial design, conduct (non-voting TSC member), 
data analysis and interpretation, manuscript writing, or dissemination of the results.   
AstraZeneca has provided the investigational medicinal product (IMP). AstraZeneca 
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reviewed and approved the protocol. The company does not have any role in the 
conduct of the trial, analysis of the data, or publication of the results. 
The MRI sub-study will involve imaging and analyses technologies provided by 
Siemens Healthcare. 
The trial is co-sponsored by NHS Greater Glasgow & Clyde and the University of 
Glasgow. C.B. is supported by funding from the British Heart Foundation 
(RE/18/6134217). 
Registration 
The ClinicalTrials.gov registration for this study is NCT04097314 
Statement of informed consent 
Written informed consent is an eligibility criterion and is required before any study 
assessments are undertaken.  Our informed consent form covers the genetic 
screening test for eligibility, the screening phase, the run-in-phase and the 
randomized study. Additionally, participants will be invited to provide optional 
consent for follow-up using electronic linkage of NHS and government records in the 
longer term.  Ongoing consent will be confirmed during each study visit. Should 
consent be withdrawn then the participant will be withdrawn from the study without 
affecting her/his standard of care. 
Discussion 
Precision medicine aims to individualize patient care bringing more effective 
therapy, while reducing both risks to patients and pressure on healthcare systems by 
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avoiding unnecessary treatments and investigations.(56)  Recent position papers 
emphasize the vital role of genetic data, accurate diagnostic tests and novel 
pathophysiological insights in the development of precision cardiovascular medicine. 
(57) 
In recent years, there have been significant advances in the understanding of the 
pathophysiology and diagnosis of microvascular angina. However, treatment has 
lagged behind. Currently, there are no disease-modifying therapies for microvascular 
angina. (3,58,59)  Instead, management remains mostly empirical with a “trial-and-
error” approach being commonplace with an unsatisfactory trend towards 
polypharmacy and repeated clinic visits. Chronic, refractory symptoms are the norm. 
Historically, cognitive bias towards coronary heart disease (predominately focusing 
on epicardial coronary artery disease), combined with the lack of specific treatments 
for microvascular angina, has led to therapeutic nihilism amongst many 
clinicians.(60) 
Phenome wide association studies (PheWAS) have provided insight on the polygenic 
nature of several common diseases and more than 100 genetic loci associated with 
CAD have already been identified.(61,62) The rs9349379 gene variant provides an 
unique opportunity to enhance the therapeutic index of ETA antagonist therapy and 
champions precision medicine. 
To our knowledge, PRIZE is the first to apply pharmacogenomics to a randomized 
controlled trial in stable ischemic heart disease. As such, this experience will have 
transferable implications for clinical practice and trials in the future. We aim to 
advance precision medicine in microvascular angina through mechanistic outcomes.  
We will collect information on participants’ characteristics at baseline including 
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medical history, health status, medication, rs9349379 genotype, and exercise 
tolerance. The participants will be invited to give informed consent for life-long 
follow-up by linkage of electronic patient records.  We have designed a bespoke 
angina diary that will provide quantitative data to correlate with the nature, 
frequency and severity of symptoms. Using multivariable analyses we will link 
baseline patient characteristics to treatment response with contemporary angina 
therapy.   
Recent studies have challenged the long-held view that microvascular angina is a 
prognostically benign condition, reporting increased rates of major adverse 
cardiovascular events (MACE). (63,64) New medicines are urgently required for 
these patients with an unmet clinical need. Should our hypotheses be confirmed, this 
developmental clinical trial will inform the rationale and design for undertaking a 
larger multicenter trial. 
Limitations 
The protocol involves sequential treatment from Phase 1 to Phase 2 without a 
washout period. The duration of treatment (12 weeks) is longer than in pivotal trials 
of evidence-based anti-anginal drugs and should be sufficient to represent chronic 
maintenance therapy.(52,65–68) Realistically, the effects of treatment with 
zibotentan, notably attenuation of vasoconstriction, are unlikely to persist during 
chronic treatment with placebo for 12 weeks.  There are also potential limitations 
with a washout period since it could increase the possibility of unblinding by giving 
the participants additional insights into the effects of the trial medication and the 
washout period would also prolong the trial.  
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Table I: Coronary Vasomotion Disorders International Study (COVADIS) 
clinical criteria for the diagnosis of microvascular angina. 
COVADIS criteria for microvascular angina 
1. Symptoms of myocardial 
ischemia 
 Effort and/or rest angina 
 Angina equivalents (i.e. shortness of breath) 
2. Absence of obstructive CAD 
(>50% diameter reduction 
and/or FFR <0.80) by either: 
 CT coronary angiography (CTCA) 
 Invasive coronary angiography 
3. Objective evidence of 
myocardial ischemia 
 Ischemic ECG changes during an episode of 
chest pain 
 Stress-induced chest pain and/or ischemic ECG 
changes in the presence of transient/reversible 
abnormal myocardial perfusion and/or wall 
motion abnormality 
4. Evidence of impaired 
coronary microvascular 
function 
 Impaired coronary flow reserve (cut-off values 
depending on methodology use between ≤2.0 
and ≤2.5) 
 Coronary microvascular spasm, defined as 
reproduction of symptoms, ischemic ECG shifts 
but no epicardial spasm during acetylcholine 
testing. 
 Abnormal coronary microvascular resistance 
indices (e.g. IMR >25, HMR ≥2.5 mm Hg·cm-
1·s) (69) 
 Coronary slow flow phenomenon 
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Table II: Exclusion criteria 
Exclusion criteria 
1. Exercise tolerance >540 seconds in men and >430 seconds in women  during Full Bruce 
protocol or, lack of anginal symptoms and/or ST-segment depression (≥0.1 mV) limiting 
exercise. 
2. Non-cardiovascular exercise-limiting problem e.g. morbid (or severe) obesity (BMI ≥40.0 
kg/m2)  
3. Genotype not available 
4. Women who are pregnant, breast-feeding or of child-bearing potential (WoCBP) without a 
negative pregnancy test 
5. Men who are sexually active with a WoCBP who are unwilling to highly effective methods of 
contraception for the duration of study treatment and for 14 weeks after the last dose of study 
drug. 
6. Heart failure (New York Heart Association Grade ≥II, i.e. mild symptoms and slight limitation 
during ordinary activity) 
7. Recent (<3 months) myocardial infarction 
8. A history of epilepsy, other CNS adverse events, neurologic symptoms or signs consistent with 
spinal cord compression or CNS metastases. 
9. Moderate or more severe renal impairment (GFR < 45 mL/min) 
10. Liver disease with a Child-Pugh score of A (5-6 points) or higher  
11. Participation in another intervention study involving a drug within the past 90 days 
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Table III: Secondary outcomes 
Secondary outcomes 
Exercise test  Time (s) to 1 mV ST depression 
 Maximum ST-segment deviation (mV) 
 Time (s) to 75% of max age-related heart 
rate during exercise 
 Metabolic equivalent (METs) 
 The DUKE Score (70) 
Health Status 
Questionnaires 
 Seattle Angina Questionnaire (SAQ) (43) 
 Illness perception 
 (Brief IPQ) (48) 
 Anxiety/depression 
 (PHQ4) (50) 
 Treatment satisfaction 
 (TSQM)(49) 
 EQ-5D-5L (47) 
Safety  Frequency and severity of severe adverse 
events (SAEs) 
Feasibility  Participant withdrawal rate 
Efficacy  Pharmacokinetics 
 Pharmacodynamics 
Exploratory endpoints/outcomes 
Patient-Reported Outcome 
Measures (PROMS) 
 Angina diary 
 
Journal Pre-proof
Jou
rna
l Pr
e-p
roo
f
 
35 
Figure I: Summary of the rationale for treatment with an ETA antagonist in microvascular angina and for rs9349379 as 
theragnostic biomarker. 
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Figure II: Schematic study design: flow diagram. 
 
Abbreviations: Blood tests (B), Clinical review (C), Exercise tolerance test (ETT; Bruce protocol), GB – genomic blood test, 
Questionnaires (Q), Stress perfusion cardiac magnetic resonance imaging (spCMR; optional sub-study), Pharmacokinetic and 
Pharmacodynamic sampling (PK/PD). 
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